These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 24350901)

  • 1. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis.
    van Bon L; Affandi AJ; Broen J; Christmann RB; Marijnissen RJ; Stawski L; Farina GA; Stifano G; Mathes AL; Cossu M; York M; Collins C; Wenink M; Huijbens R; Hesselstrand R; Saxne T; DiMarzio M; Wuttge D; Agarwal SK; Reveille JD; Assassi S; Mayes M; Deng Y; Drenth JP; de Graaf J; den Heijer M; Kallenberg CG; Bijl M; Loof A; van den Berg WB; Joosten LA; Smith V; de Keyser F; Scorza R; Lunardi C; van Riel PL; Vonk M; van Heerde W; Meller S; Homey B; Beretta L; Roest M; Trojanowska M; Lafyatis R; Radstake TR
    N Engl J Med; 2014 Jan; 370(5):433-43. PubMed ID: 24350901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution to the peripheral vasculopathy and endothelial cell dysfunction by CXCL4 in Systemic Sclerosis.
    Jiang Z; Chen C; Yang S; He H; Zhu X; Liang M
    J Dermatol Sci; 2021 Oct; 104(1):63-73. PubMed ID: 34556381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia and TLR9 activation drive CXCL4 production in systemic sclerosis plasmacytoid dendritic cells via mtROS and HIF-2α.
    Ottria A; Zimmermann M; Paardekooper LM; Carvalheiro T; Vazirpanah N; Silva-Cardoso S; Affandi AJ; Chouri E; V D Kroef M; Tieland RG; Bekker CPJ; Wichers CGK; Rossato M; Mocholi-Gimeno E; Tekstra J; Ton E; van Laar JM; Cossu M; Beretta L; Garcia Perez S; Pandit A; Bonte-Mineur F; Reedquist KA; van den Bogaart G; Radstake TRDJ; Marut W
    Rheumatology (Oxford); 2022 May; 61(6):2682-2693. PubMed ID: 34559222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon-α production in systemic sclerosis.
    Lande R; Lee EY; Palazzo R; Marinari B; Pietraforte I; Santos GS; Mattenberger Y; Spadaro F; Stefanantoni K; Iannace N; Dufour AM; Falchi M; Bianco M; Botti E; Bianchi L; Alvarez M; Riccieri V; Truchetet ME; C L Wong G; Chizzolini C; Frasca L
    Nat Commun; 2019 May; 10(1):1731. PubMed ID: 31043596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteome-wide analysis and CXCL4 in systemic sclerosis.
    George PM; Wort SJ; Mitchell JA
    N Engl J Med; 2014 Apr; 370(16):1561-2. PubMed ID: 24738677
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-CXCL4 Antibody Reactivity Is Present in Systemic Sclerosis (SSc) and Correlates with the SSc Type I Interferon Signature.
    Lande R; Mennella A; Palazzo R; Pietraforte I; Stefanantoni K; Iannace N; Butera A; Boirivant M; Pica R; Conrad C; Chizzolini C; Riccieri V; Frasca L
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32707718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteome-wide analysis and CXCL4 in systemic sclerosis.
    Mathian A; Miyara M; Gorochov G
    N Engl J Med; 2014 Apr; 370(16):1562. PubMed ID: 24738679
    [No Abstract]   [Full Text] [Related]  

  • 8. Proteome-wide analysis and CXCL4 in systemic sclerosis.
    Su R; Schmajuk G
    N Engl J Med; 2014 Apr; 370(16):1562. PubMed ID: 24738678
    [No Abstract]   [Full Text] [Related]  

  • 9. Proteome-wide analysis and CXCL4 in systemic sclerosis.
    van Roon JA; Tesselaar K; Radstake TR
    N Engl J Med; 2014 Apr; 370(16):1563-4. PubMed ID: 24738676
    [No Abstract]   [Full Text] [Related]  

  • 10. Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8.
    Ah Kioon MD; Tripodo C; Fernandez D; Kirou KA; Spiera RF; Crow MK; Gordon JK; Barrat FJ
    Sci Transl Med; 2018 Jan; 10(423):. PubMed ID: 29321259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CXCL4-RNA Complexes Circulate in Systemic Sclerosis and Amplify Inflammatory/Pro-Fibrotic Responses by Myeloid Dendritic Cells.
    Pietraforte I; Butera A; Gaddini L; Mennella A; Palazzo R; Campanile D; Stefanantoni K; Riccieri V; Lande R; Frasca L
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCL4 drives fibrosis by promoting several key cellular and molecular processes.
    Affandi AJ; Carvalheiro T; Ottria A; de Haan JJ; Brans MAD; Brandt MM; Tieland RG; Lopes AP; Fernández BM; Bekker CPJ; van der Linden M; Zimmermann M; Giovannone B; Wichers CGK; Garcia S; de Kok M; Stifano G; Xu YJ; Kowalska MA; Waasdorp M; Cheng C; Gibbs S; de Jager SCA; van Roon JAG; Radstake TRDJ; Marut W
    Cell Rep; 2022 Jan; 38(1):110189. PubMed ID: 34986347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [CXCL4: a new biomarker of diagnosis and severity in systemic sclerosis?].
    Marie I
    Rev Med Interne; 2015 Feb; 36(2):69-72. PubMed ID: 25458865
    [No Abstract]   [Full Text] [Related]  

  • 14. Low heme oxygenase-1 levels in patients with systemic sclerosis are associated with an altered Toll-like receptor response: another role for CXCL4?
    van Bon L; Cossu M; Scharstuhl A; Pennings BW; Vonk MC; Vreman HJ; Lafyatis RL; van den Berg W; Wagener FA; Radstake TR
    Rheumatology (Oxford); 2016 Nov; 55(11):2066-2073. PubMed ID: 27411481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CXCL4 triggers monocytes and macrophages to produce PDGF-BB, culminating in fibroblast activation: Implications for systemic sclerosis.
    van der Kroef M; Carvalheiro T; Rossato M; de Wit F; Cossu M; Chouri E; Wichers CGK; Bekker CPJ; Beretta L; Vazirpanah N; Trombetta E; Radstake TRDJ; Angiolilli C
    J Autoimmun; 2020 Jul; 111():102444. PubMed ID: 32284212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of cytokines CXCL4, CXCL8 and GDF15 as biomarkers in systemic sclerosis.
    Oller-Rodríguez JE; Vicens Bernabeu E; Gonzalez-Mazarío R; Grau García E; Ortiz Sanjuan FM; Román Ivorra JA
    Med Clin (Barc); 2022 Oct; 159(8):359-365. PubMed ID: 35039167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated expression of platelet-derived chemokines in patients with antiphospholipid syndrome.
    Patsouras MD; Sikara MP; Grika EP; Moutsopoulos HM; Tzioufas AG; Vlachoyiannopoulos PG
    J Autoimmun; 2015 Dec; 65():30-7. PubMed ID: 26283469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCL4 is a driver of cytokine mRNA stability in monocyte-derived dendritic cells.
    Silva-Cardoso SC; Bekker CPJ; Boes M; Radstake TRDJ; Angiolilli C
    Mol Immunol; 2019 Oct; 114():524-534. PubMed ID: 31518856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on biomarker discovery and use in systemic sclerosis.
    Matsushita T; Takehara K
    Expert Rev Mol Diagn; 2017 Sep; 17(9):823-833. PubMed ID: 28730919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low RUNX3 expression alters dendritic cell function in patients with systemic sclerosis and contributes to enhanced fibrosis.
    Affandi AJ; Carvalheiro T; Ottria A; Broen JC; Bossini-Castillo L; Tieland RG; Bon LV; Chouri E; Rossato M; Mertens JS; Garcia S; Pandit A; de Kroon LM; Christmann RB; Martin J; van Roon JA; Radstake TR; Marut W
    Ann Rheum Dis; 2019 Sep; 78(9):1249-1259. PubMed ID: 31126957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.